MiCo BioMed Balance Sheet Health
Financial Health criteria checks 5/6
MiCo BioMed has a total shareholder equity of ₩36.3B and total debt of ₩10.4B, which brings its debt-to-equity ratio to 28.7%. Its total assets and total liabilities are ₩61.3B and ₩25.0B respectively.
Key information
28.7%
Debt to equity ratio
₩10.44b
Debt
Interest coverage ratio | n/a |
Cash | ₩22.64b |
Equity | ₩36.33b |
Total liabilities | ₩24.99b |
Total assets | ₩61.32b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A214610's short term assets (₩47.4B) exceed its short term liabilities (₩17.5B).
Long Term Liabilities: A214610's short term assets (₩47.4B) exceed its long term liabilities (₩7.5B).
Debt to Equity History and Analysis
Debt Level: A214610 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A214610's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A214610 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A214610 has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 7.7% each year.